Jan C. Fagerberg

62 year

Health Technology

Consumer Services

Profile

Jan C.
Fagerberg served as the Chief Medical Officer & SVP at Amgen Rockville, Inc. from 2009 to 2011.
Prior to that, he was the Medical Director at Topotarget A in 2009.
He also served as an Independent Director at Response Genetics, Inc. in 2010 and 2011.
Fagerberg earned a doctorate degree from Karolinska Institutet in 1988.

Former positions of Jan C. Fagerberg

Companies	Position	End
RESPONSE GENETICS, INC	Director/Board Member	2011-10-11
TOPOTARGET A/S	Chief Tech/Sci/R&D Officer	2008-12-31
Amgen Rockville, Inc. Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD.	Chief Tech/Sci/R&D Officer	-

See the detail of Jan C. Fagerberg's experience

Training of Jan C. Fagerberg

Karolinska Institutet

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Jan C. Fagerberg's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
RESPONSE GENETICS, INC	Health Technology

Private companies	2
Amgen Rockville, Inc. Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD.	Health Technology
Topotarget A/S Topotarget A/S Pharmaceuticals: MajorHealth Technology Topotarget A/S is a biotechnology company that is engaged in the development and commercialization of novel drugs for the treatment of cancer. Its product belinostat is a novel histone deacetylase inhibitor which is used for cancer patients. The company was founded by Peter Buhl Jensen and Maxwell Sehested in 2000 and is headquartered in Copenhagen, Denmark.	Health Technology